top of page

Research Blog


We are pleased to announce that Marta has been awarded a prestigious Vidi grant from the Dutch Research Council (NWO). The grant, providing up to €850,000 over five years, will support her SHIELD project, which aims to develop effective cancer immunotherapies while preserving the immune system's ability to protect patients against viral infections.


Advancing cancer immunotherapy to preserve protective immunity against infections

Immunotherapy uses our body’s natural immune response to fight cancer. However, current cancer immunotherapies deplete certain immune cells that protect the body against viruses. As a result, half of the patients treated with T-cell engagers, a specific form of immune redirecting therapy, develop life-threatening infections.

 

In SHIELD, Marta will develop cancer therapies that activate various types of immune cells continuously produced in our bodies, while maintaining virus control. “We will develop a strategy to identify which patients are at risk of severe, long-lasting infections, and the biological reasons behind it.”

To test the effectiveness of this approach, Marta and her team will develop a culture model with patient cells. “Our goal is to develop effective anti-cancer immunotherapies that keep patients able to clear infections fast, which could make a real difference to their quality of life.”


Congratulations to Marta on this achievement, and looking forward to the next steps of the SHIELD project!

 
 

Bijgewerkt op: 12 jan.

Jan 7, 2026: Successful PhD thesis defense of Thomas Kimman, entitled;                                                         Empowering CAR T cell therapy - Translating resistance mechanisms into opportunities
Jan 7, 2026: Successful PhD thesis defense of Thomas Kimman, entitled; Empowering CAR T cell therapy - Translating resistance mechanisms into opportunities


 
 

Bijgewerkt op: 24 sep. 2025

We’re excited to share our latest publication in iScience!


Our study shows that the 3D culture matrix strongly influences T cell and CAR-T cell function. We found that a synthetic nanofibrillar cellulose (NFC) hydrogel maintained T cell activity, whereas Matrigel and BME reduced their function — underscoring the importance of choosing the right matrix for reliable preclinical testing.


📖 Read the open-access article: Via iScience | Via PubMed


 
 
2

Contact
Information

Center for Translational Immunology

University Medical Center Utrecht

Heidelberglaan 100

3584 CX Utrecht, Netherlands

Thanks for submitting!

©2035 by Daniel Tenant. Powered and secured by Wix

bottom of page